| This report covers different regional application | | | | Company strategy 143 |
| markets, while evaluating them over the next five | | | | Capsulution Nanoscience AG 144 |
| years. It provides information about the largest regional | | | | Company overview 144 |
| markets and factors influencing them, while defining the | | | | Products and services 144 |
| opportunities they present. | | | | Company strategy 144 |
| Key features of this report | | | | ConvaTec 145 |
| • •Provides an analysis of market data | | | | Company overview 145 |
| (revenues) of healthcare nanotechnology applications | | | | Products and services 145 |
| in North America, Europe, Asia and Rest of World that | | | | Company strategy 146 |
| includes Middle East, Africa, Russia, Latin America and | | | | Debiotech 146 |
| Australia. | | | | Company overview 146 |
| • Studies key market drivers and restraints for the | | | | Products and services 146 |
| main market and evaluation of respective sub | | | | Company strategy 147 |
| segments with respect to market dynamics. | | | | Do-Coop Technologies Ltd. 147 |
| • Discusses drug delivery and formulations, | | | | Company overview 147 |
| biocompatible implants, regenerative medicine and | | | | Products and services 147 |
| wound care and diagnostics under the applications | | | | Company strategy 148 |
| market along with related sub segments. | | | | Elan Corp. 148 |
| Scope of this report | | | | Company overview 148 |
| • Understanding the existing and emerging | | | | Products and services 148 |
| applications of healthcare nanotechnology and their | | | | Company strategy 149 |
| relative and forecast market sizes | | | | Ferro Corp. 149 |
| • Understanding the product/technological | | | | Company overview 149 |
| developments on which the companies are focusing | | | | Products and services 150 |
| for their growth. | | | | Company strategy 150 |
| • Understanding the different nanotechnology based | | | | Flamel Technologies 150 |
| tools and their importance in the development of new | | | | Company overview 151 |
| products and applications | | | | Products and services 151 |
| Key Market Issues | | | | Company strategy 151 |
| • Nanotechnology initiatives by developing countries | | | | GE Global Research 152 |
| are helping in the development of new products and | | | | Company overview 152 |
| applications. | | | | Company strategy 152 |
| • The delay in commercialization due to strict | | | | GfE Medizintechnik GmbH 153 |
| regulations and manufacturing difficulties is inhibiting | | | | Company overview 153 |
| product reach. | | | | Products and services 153 |
| • Stability of nanoparticles inside the biological | | | | Company strategy 154 |
| tissues is an important issue to be considered to | | | | HemCon Medical Technologies, Inc. 154 |
| reduce contamination by drugs. | | | | Company overview 154 |
| • The development of biodegradable | | | | Company strategy 155iCeutica Inc 155 |
| nanostructures will be a growth driver in future since | | | | Company overview 155 |
| they eliminate the issue of excretion. | | | | Products and services 156 |
| Key findings from this report | | | | Company strategy 156 |
| • The healthcare nanotechnology market growth is | | | | Liquidia Technologies 157 |
| largest in North America, at $4.75bn in 2009, followed | | | | Company overview 157 |
| by Europe at $3.65. | | | | Company strategy 157 |
| • The nanotechnology drug delivery market is | | | | Luna Innovations Inc. 158 |
| expected to grow at a CAGR of 21.7% for the period | | | | Company overview 158 |
| 2009-14, to reach almost $16bn by 2014. | | | | Products and services 158 |
| • Biocompatible implants and coatings and | | | | Company strategy 159 |
| diagnostics comprise some of the major applications | | | | MagForce Nanotechnologies AG 159 |
| which are estimated to experience high growth | | | | Company overview 160 |
| between 2009 and 2014, 42% and 21.8% respectively. | | | | Products and services 160 |
| Key questions answered | | | | Company strategy 161 |
| • What are the important healthcare | | | | Merck KGaA 161 |
| nanotechnology markets and their growth over the | | | | Company overview 161 |
| period 2009-14? | | | | Products and services 162 |
| • What are the major applications that have | | | | Company strategy 162 |
| emerged in different areas such as drug formulations | | | | MIV Therapeutics Inc 162 |
| and delivery, biocompatible implants and coatings, | | | | Company overview 163 |
| regenerative medicines and wound care and | | | | Products and services 163 |
| diagnostics? | | | | Company strategy 163 |
| • In which areas are the companies focusing while | | | | Nanomix 163 |
| forming strategic alliances with other industry players? | | | | Company overview 164 |
| Table of Contents | | | | Products and services 164 |
| Nanotechnology in Healthcare | | | | Company strategy 164 |
| Executive summary 16 | | | | Nano Interface Technology, Inc 165 |
| Market overview 16 | | | | Company overview 165 |
| Healthcare nanotechnology market dynamics 16 | | | | Products and services 165 |
| Nanomaterials & nanotools for the healthcare | | | | Company strategy 165 |
| market 17 | | | | NanoCarrier Co., Ltd. 165 |
| Healthcare nanotechnology application market 18 | | | | Company overview 166 |
| Company profiles 19 | | | | Products and services 166 |
| Chapter 1 Market overview 22 | | | | Company strategy 166 |
| Summary 22 | | | | NanoDel Technologies 167 |
| Introduction 23 | | | | Company overview 167 |
| Market definition 23 | | | | Products and services 167 |
| Healthcare nanotechnology business processes 24 | | | | Company strategy 167 |
| Healthcare nanotechnology applications 24 | | | | NanoHorizons Inc. 168 |
| Healthcare nanotechnology application prospects 25 | | | | Company overview 168 |
| Opportunity matrix 26 | | | | Products and services 168 |
| Challenge matrix 28 | | | | Company strategy 168 |
| Patent analysis 29 | | | | Nanoprobes, Inc. 169 |
| Chapter 2 Healthcare nanotechnology market | | | | Company overview 169 |
| dynamics 34 | | | | Products and services 169 |
| Summary 34 | | | | Company strategy 169 |
| Introduction 35 | | | | Nanospectra Biosciences Inc. 170 |
| Regional markets 36 | | | | Company overview 170 |
| North America 37 | | | | Products and services 170 |
| Europe 38 | | | | Company strategy 170 |
| Asia 38 | | | | Nanosphere, Inc. 171 |
| RoW 39 | | | | Company overview 171 |
| Competitive landscape 39 | | | | Products and services 171 |
| R&D activities by applications 41 | | | | Company strategy 172 |
| New product launches 42 | | | | Novartis AG 172 |
| Collaborations & agreements 43 | | | | Company overview 173 |
| Market drivers 56 | | | | Products and services 173 |
| Nanotechnology research initiatives in developing | | | | Company strategy 173 |
| nations 56 | | | | Pfizer 173 |
| Innovations are increasing 56 | | | | Company overview 173 |
| Reduced toxicity 56 | | | | Company strategy 174 |
| Market inhibitors 57 | | | | PharmaSol GmbH 174 |
| Delay in commercialization 57 | | | | Company overview 174 |
| Stability and other issues 57 | | | | Products and services 174 |
| Need for particle evaluation 57 | | | | Company strategy 175 |
| Chapter 3 Nanomaterials & nanotools for the | | | | Pioneer Surgical Technology 175 |
| healthcare market 60 | | | | Company overview 175 |
| Summary 60 | | | | Products and services 175 |
| Introduction 61 | | | | Company strategy 176pSivida 176 |
| Nanomaterials 61 | | | | Company overview 176 |
| Nanocapsules 61 | | | | Products and services 176 |
| Drivers 61 | | | | Company strategy 176 |
| Inhibitors 62 | | | | F. Hoffmann–La Roche Ltd. 177 |
| Opportunities 62 | | | | Company overview 177 |
| Nanoporous materials 63 | | | | Products and services 177 |
| Drivers 63 | | | | Company strategy 177 |
| Opportunities 63 | | | | Siemens Medical Solutions 178 |
| Quantum dots 63 | | | | Company overview 178 |
| Drivers 64 | | | | Products and services 179 |
| Inhibitors 64 | | | | Company strategy 179 |
| Opportunities 64 | | | | Smith & Nephew 179 |
| Nanotubes 65 | | | | Company overview 179 |
| Drivers 65 | | | | Products and services 180 |
| Nanowires 65 | | | | Company strategy 180 |
| Drivers 66 | | | | Starpharma Holdings Ltd. 181 |
| Inhibitors 66 | | | | Company overview 181 |
| Opportunities 66 | | | | Products and services 181 |
| Dendrimers 67 | | | | Company strategy 182 |
| Drivers 67 | | | | T2 Biosystems Inc. 183 |
| Opportunities 68 | | | | Company overview 183 |
| Monoclonal antibodies 68 | | | | Company strategy 183 |
| Drivers 68 | | | | Appendix 184 |
| Inhibitors 69 | | | | Patents 184 |
| Opportunities 69 | | | | Glossary 218 |
| Nanocomposites 69 | | | | List of Figures |
| Fullerenes 70 | | | | Figure 1.1: Global healthcare nanotechnology market 23 |
| Nanofilms 70 | | | | Figure 1.2: Geographical patent share, 2003-08 30 |
| Drivers 71 | | | | Figure 1.3: Number of patents by region, 2003-09 30 |
| Inhibitors 71 | | | | Figure 1.4: Comparison of patent trends, 2004 vs 2009 |
| Opportunities 71 | | | | 31 |
| Nanotools 72 | | | | Figure 2.5: Developmental strategies by major players, |
| Nanoarrays 72 | | | | January 2007–November 2009 40 |
| Drivers 72 | | | | Figure 2.6: R&D activities by applications, Jan |
| Inhibitors 73 | | | | 2007–Nov 2009 41 |
| Opportunities 73 | | | | Figure 2.7: New product launches, Jan 2007–Nov |
| Nanobiochip 74 | | | | 2009 42 |
| Drivers 74 | | | | Figure 2.8: Collaborations & agreements by |
| Opportunities 75 | | | | applications, Jan 2007–Nov2009 43 |
| Nanolithography arrays 75 | | | | Figure 2.9: Relative importance of features of |
| Drivers 75 | | | | healthcare nanotechnology 58 |
| Inhibitors 76 | | | | List of Tables |
| Opportunities 76 | | | | Table 2.1: Global healthcare nanotech market, by |
| Computer-assisted drug discovery 77 | | | | geography ($m), 2007-14 37 |
| Nanomass spectrometry 77 | | | | Table 2.2: Mergers & acquisitions in healthcare |
| Drivers 77 | | | | nanotech market, 2007–09 44 |
| Inhibitors 78 | | | | Table 2.3: New product launches in healthcare |
| Opportunities 78 | | | | nanotech market, 2007–09 45 |
| Congruent Force Intermolecular Test (nanotype) C-FIT | | | | Table 2.4: New product launches in healthcare |
| 78 | | | | nanotech market, 2007–09 (ctd) 46 |
| Chapter 4 Healthcare nanotechnology application | | | | Table 2.5: R&D in healthcare nanotech market, |
| market 82 | | | | 2007–09 47 |
| Summary 82 | | | | Table 2.6: R&D in healthcare nanotech market, |
| Introduction 83 | | | | 2007–09 (ctd 1) 48 |
| Drug formulation and delivery 83 | | | | Table 2.7: R&D in healthcare nanotech market, |
| Formulation 84 | | | | 2007–09 (ctd 2) 49 |
| Drivers 85 | | | | Table 2.8: R&D in healthcare nanotech market, |
| Inhibitors 86 | | | | 2007–09 (ctd 3) 50 |
| Opportunities 86 | | | | Table 2.9: R&D in healthcare nanotech market, |
| Fluorescently encoded microparticles 86 | | | | 2007–09 (ctd 4) 51 |
| Nanoparticulate formulation/systems 88 | | | | Table 2.10: R&D in healthcare nanotech market, |
| Fluoropolymers as material platforms for drug therapy | | | | 2007–09 (ctd 5) 52 |
| 88 | | | | Table 2.11: R&D in healthcare nanotech market, |
| DNA nanoparticle technology to produce DNA drugs | | | | 2007–09 (ctd 6) 53 |
| 89 | | | | Table 2.12: Collaborations & agreements in |
| Drug profiling using smart materials 90 | | | | healthcare nanotech market, 2007–09 54 |
| Supercritical fluids and water based nanomaterials 91 | | | | Table 2.13: Collaborations & agreements in |
| Dendrimer nanotechnology products 92 | | | | healthcare nanotech market, 2007–09 (ctd) 55 |
| Potential healthcare nanotechnology drug formulation | | | | Table 4.14: Global healthcare nanotech drug formulation |
| application 93 | | | | and delivery market, by product ($m), 2007–14 83 |
| Drug delivery 93 | | | | Table 4.15: Global healthcare nanotech drug formulation |
| Drivers 94 | | | | and delivery market, by geography ($m), 2007–14 |
| Inhibitors 95 | | | | 84 |
| Opportunities 95 | | | | Table 4.16: Global healthcare nanotechnology drug |
| Nanoencapsulation using nano-device platform 96 | | | | formulation market, by product ($m), 2007–14 85 |
| Smart materials for encapsulation 97 | | | | Table 4.17: Global healthcare nanotech fluorescently |
| Antimicrobial nanoencapsulation 98 | | | | encoded microparticles market, by geography ($m), |
| Nanoscale cochlear drug delivery 99 | | | | 2007–14 87 |
| Drug delivery using nanoparticles 99 | | | | Table 4.18: Global healthcare nanotech nanoparticulate |
| Nanocrystals for drug delivery 102 | | | | formulation/systems market, by geography ($m), |
| Drug delivery coatings 103 | | | | 2007–14 88 |
| Nanopores 103 | | | | Table 4.19: Global healthcare nanotech fluoropolymers |
| Nanocomposites 104 | | | | material platforms for drug therapy market, by |
| Nanotransponders 105 | | | | geography ($m), 2007–14 89 |
| Potential applications of healthcare nanotechnology | | | | Table 4.20: Global healthcare DNA nanoparticle |
| drug delivery 105 | | | | technology to produce DNA drugs market, by |
| Biocompatible implants and coatings 106 | | | | geography ($m), 2007-14 90 |
| Drivers 108 | | | | Table 4.21: Global healthcare nanotech drug profiling |
| Nanofibers fight immune response 108 | | | | using smart materials market, by geography ($m), |
| Improvement in biocompatibility 108 | | | | 2007-14 91 |
| Optimized coatings 108 | | | | Table 4.22: Global healthcare nanotech supercritical |
| Improvement in dental implants 108 | | | | fluids and water based nanomaterials market, by |
| Inhibitors 108 | | | | geography ($m), 2007-14 91 |
| Improvement of implant depends upon coatings 108 | | | | Table 4.23: Global dendrimer nanotech products |
| Possibility of mass poisoning 109 | | | | market by geography ($m), 2007-14 92 |
| Opportunities 109 | | | | Table 4.24: Global healthcare nanotech drug delivery |
| Improved brain implants 109 | | | | market by product ($m), 2007-14 94 |
| Improvement in process for better coatings 109 | | | | Table 4.25: Global healthcare nanoencapsulation using |
| Helpful in orthopedic devices 109 | | | | nano-device platform market, by product ($m), 2007-14 |
| Surface modification 109 | | | | 96 |
| Device coating 110 | | | | Table 4.26: Global healthcare nanoencapsulation using |
| Drivers 112 | | | | nano-device platform market, by geography ($m), |
| Inhibitors 112 | | | | 2007-14 97 |
| Opportunities 112 | | | | Table 4.27: Global market for smart materials |
| Sol-gel coatings 113 | | | | encapsulating pharmaceuticals, by geography ($m), |
| Biocompatible nanocoatings 113 | | | | 2007-14 98 |
| Nanoscale plasma coating 113 | | | | Table 4.28: Global healthcare nanotech antimicrobial |
| Light-activated antimicrobials 113 | | | | nanoencapsulation, by geography ($m), 2007-14 98 |
| Silver nanoparticles 114 | | | | Table 4.29: Global healthcare nanotech nanoscale |
| Hydrophobic coatings 114 | | | | cochlear drug delivery, by geography ($m), 2007-14 99 |
| Multifunctional coatings 114 | | | | Table 4.30: Global healthcare nanotech drug delivery |
| Anti-fouling nanocoatings 114 | | | | using nanoparticles market, by product ($m), 2007-14 |
| Passive hydroxyapatite coating 115 | | | | 100 |
| Other protective coatings 115 | | | | Table 4.31: Global healthcare nanotech drug delivery |
| Implants 116 | | | | using nanoparticles market, by geography ($m), |
| Drivers 116 | | | | 2007-14 100 |
| Opportunities 117 | | | | Table 4.32: Global drug delivery using nanocrystals |
| Potential biocompatible implants applications 117 | | | | market, by geography ($m), 2007-14 102 |
| Life support devices using novel biocompatible | | | | Table 4.33: Global healthcare nanotech drug delivery |
| polymers 117 | | | | coatings market, by geography ($m), 2007- 14 103 |
| Stimulation electrodes using nanotechnology 117 | | | | Table 4.34: Global healthcare nanopores market, by |
| Noninvasive killing of cancer cells using localized heat | | | | geography ($m), 2007-14 104 |
| 118 | | | | Table 4.35: Global healthcare nanocomposites market, |
| Artificial vascular grafts 118 | | | | by geography ($m), 2007-14 104 |
| Bone graft substitutes 118 | | | | Table 4.36: Global healthcare nanotech |
| Regenerative medicine and wound care 118 | | | | nanotransponder market, by geography ($m), 2007-14 |
| Regenerative medicine/tissue engineering 119 | | | | 105 |
| Drivers 120 | | | | Table 4.37: Global healthcare nanotech biocompatible |
| Inhibitors 121 | | | | implants and coatings market, by products ($m), |
| Opportunities 121 | | | | 2007-14 107 |
| Potential applications of regenerative medicines 123 | | | | Table 4.38: Global healthcare nanotech biocompatible |
| Wound care 124 | | | | implants and coatings market, by geography ($m), |
| Drivers 124 | | | | 2007-14 107 |
| Opportunities 125 | | | | Table 4.39: Global healthcare nanotech surface |
| Nanosilver gels 125 | | | | modification market, by geography ($m), 2007-14 110 |
| Nanogold gels 125 | | | | Table 4.40: Global healthcare nanotech device coating |
| Diagnostics 126 | | | | market, by products ($m), 2007-14 111 |
| Drivers 127 | | | | Table 4.41: Global healthcare nanotech device coating |
| Improved bioassays 127 | | | | market, by geography ($m), 2007-14 111 |
| Earlier diagnosis and effective monitoring 127 | | | | Table 4.42: Global healthcare nanotech implants |
| Opportunities 127 | | | | market, by geography ($m), 2007-14 116 |
| Treatment of ovarian cancer 127 | | | | Table 4.43: Global healthcare nanotech regenerative |
| Development of immunoassays 128 | | | | medicine and wound care market, by products |
| Quantum dots applications 128 | | | | ($m), 2007-14 119 |
| Nanoemulsions in multimodal molecular imaging and | | | | Table 4.44: Global healthcare nanotech regenerative |
| targeted therapeutics 128 | | | | medicine market, by product ($m), 2007-14 120 |
| Nanoparticles for biochemical applications 129 | | | | Table 4.45: Global healthcare nanotech wound care |
| Magnetic nanoparticles for medical diagnostic imaging | | | | market, by products ($m), 2007-14 124 |
| 129 | | | | Table 4.46: Global healthcare nanotech diagnostics |
| Encapsulation of radioactive nanoparticle 129 | | | | market, by products ($m), 2007-14 126 |
| Genome sequencing 129 | | | | Table 4.47: Global healthcare nanotech diagnostics |
| Nanobiosensors 130 | | | | market, by geography ($m), 2007-14 127 |
| Nanoarray biochips 130 | | | | Table 0.48: US patents 184 |
| Silicon-based chips/sensors for pH and pressure 130 | | | | Table 0.49: US patents (ctd 1) 185 |
| Micro- and nano-replication for point-of-use analytical | | | | Table 0.50: US patents (ctd 2) 186 |
| applications 131 | | | | Table 0.51: US patents (ctd 3) 187 |
| Nanocells 131 | | | | Table 0.52: US patents (ctd 4) 188 |
| Redox enzymes 131 | | | | Table 0.53: US patents (ctd 5) 189 |
| Other potential diagnostics applications 132 | | | | Table 0.54: US patents (ctd 6) 190 |
| Smart card diagnostics 132 | | | | Table 0.55: US patents (ctd 7) 191 |
| Novel microfluidic technologies 132 | | | | Table 0.56: US patents (ctd 8) 192 |
| Chapter 5 Company profiles 134 | | | | Table 0.57: US patents (ctd 9) 193 |
| Summary 134 | | | | Table 0.58: US patents (ctd 10) 194 |
| Abraxis BioScience, Inc. 135 | | | | Table 0.59: US patents (ctd 11) 195 |
| Company overview 135 | | | | Table 0.60: US patents (ctd 12) 196 |
| Products and services 135 | | | | Table 0.61: US patents (ctd 13) 197 |
| Company strategy 136 | | | | Table 0.62: US patents (ctd 14) 198 |
| Access Pharmaceuticals, Inc. 137 | | | | Table 0.63: US patents (ctd 15) 199 |
| Company overview 137 | | | | Table 0.64: US patents (ctd 16) 200 |
| Products and services 137 | | | | Table 0.65: US patents (ctd 17) 201 |
| Company strategy 138 | | | | Table 0.66: US patents (ctd 18) 202 |
| AstraZeneca 138 | | | | Table 0.67: US patents (ctd 19) 203 |
| Company overview 138 | | | | Table 0.68: Europe patents 204 |
| Products and services 139 | | | | Table 0.69: Europe patents (ctd 1) 205 |
| Company strategy 139 | | | | Table 0.70: Europe patents (ctd 2) 206 |
| AMAG Pharmaceuticals, Inc. 139 | | | | Table 0.71: Europe patents (ctd 3) 207 |
| Company overview 139 | | | | Table 0.72: Europe patents (ctd 4) 208 |
| Products and services 140 | | | | Table 0.73: Europe patents (ctd 5) 209 |
| Company strategy 140 | | | | Table 0.74: Europe patents (ctd 6) 210 |
| Aphios Corp. 140 | | | | Table 0.75: Europe patents (ctd 7) 211 |
| Company overview 141 | | | | Table 0.76: Europe patents (ctd 8) 212 |
| Products and services 141 | | | | Table 0.77: Europe patents (ctd 9) 213 |
| Company strategy 142 | | | | Table 0.78: Europe patents (ctd 10) 214 |
| Asklepios Biopharmaceutical Inc. 142 | | | | Table 0.79: Europe patents (ctd 11) 215 |
| Company overview 143 | | | | Table 0.80: Japan patents 216 |
| Products and services 143 | | | | Table 0. |